Clinical significance of COX-2, GLUT-1 and VEGF expressions in endometrial cancer tissues

ABSTRACT

To analyze the clinical significance of COX-2, GLUT-1 and VEGF expressions in endometrial cancer tissues. One hundred and eight tissue samples from the patients with endometrial cancer enrolled in our hospital from August 2011 to July 2014 were selected, including 60 normal tissue samples [normal group], 60 neoplastic tissue samples [neoplastic group] and 60 cancer tissue samples [cancer group]. All the samples were subjected to immunohistochemical assay to detect the expressions of COX-2, GLUT-1 and VEGF. The clinical data were also investigated for correlation analysis. The positive rates of COX-2 in normal group, neoplastic group and cancer groups were 3.3%, 21.7% and 55.0% respectively. The positive rates of GLUT-1 in normal group, neoplastic group and cancer groups were 3.3%, 25.0% and 70.0% respectively. The positive rates of VEGF in normal group, neoplastic group and cancer groups were 1.7%, 23.3% and 63.3% respectively. With increasing stage of such cancer, decreasing degree of differentiation and lymphatic metastasis, the positive expression rates of COX-2, GLUT-1 and VEGF proteins were raised significantly [P<0.05]. Spearman's correlation analysis showed that the expressions of COX-2 and GLUT-1 [r=0.207, P<0.05], COX-2 and VEGF [r=0.243, P<0.05], as well as GLUT-1 and VEGF [r=0.758, P<0.05] were positively correlated. COX-2, GLUT-1 and VEGF were highly prominent in endometrial cancer, especially in the patients with low degree of differentiation, late stage and metastasis. They functioned synergistically in the onset and progression of this cancer